Biogen Inc. has finalized its acquisition of Apellis Pharmaceuticals for $5.6 billion, significantly enhancing its portfolio in immune disease therapies. This move follows recent announcements of a substantial $2 billion investment in North Carolina manufacturing and securing rights to felzartamab for $850 million in Greater China. Following the acquisition, Biogen's shares rose 1.3% in premarket trading, indicating investor confidence despite navigating a mixed market landscape and anticipated challenges in integrating Apellis.
“Biogen · closed at · share price · $197.95”
“Biogen · recent 1 month share price return is · short-term performance · 14.44%”
“Biogen · 1 year total shareholder return is · performance over a year · 59.12%”
“Biogen · trading near · intrinsic discount · 54%”
“Biogen · average analyst price target is · target price · $217.03”
“Biogen · most followed narrative sets a fair value of · fair value · $205.67”
“Biogen · potential revenue paths depend on · narrow set of launches · assumption of offsetting pricing and biosimilar pressure”
“Biogen Inc. (NASDAQ:BIIB) · agreed to pay · up to $850 million · for the exclusive Greater China rights to felzartamab”
“Biogen Inc. (NASDAQ:BIIB) · shares rose · 1.3% · in premarket trading”
“Biogen Inc. (NASDAQ:BIIB) · obtained · felzartamab · as part of its $1.8 billion takeover of Human Immunology Biosciences in 2024”
“Biogen Inc. announced a research collaboration · is designed to discover and develop · oral macrocyclic peptides · for priority targets in immunological conditions”
“Biogen · acquire · a drug company · $5.6 billion”
